What is QYNAPSE?
Qynapse is a Paris-based medical technology firm specializing in quantitative imaging and artificial intelligence solutions. The company's platform is designed to optimize the diagnosis, prognosis, and longitudinal monitoring of patients affected by Alzheimer's disease and other neurological conditions. By leveraging advanced AI and imaging analysis, Qynapse aims to provide clinicians with more precise tools for patient management and therapeutic development.
How much funding has QYNAPSE raised?
QYNAPSE has raised a total of $3M across 1 funding round:
Angel/Seed
$3M
Angel/Seed (2021): $3M, investors not publicly disclosed
What's next for QYNAPSE?
The recent major strategic investment indicates Qynapse is poised for significant expansion and further development of its AI-driven diagnostic tools. This enterprise-level funding will likely fuel advancements in their technology, potentially leading to broader clinical adoption and new market penetration. The company's focus on Alzheimer's and neurological diseases positions it within a critical and growing area of healthcare innovation, suggesting a trajectory towards becoming a key player in neuro-diagnostics.
See full QYNAPSE company page
